Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

References

• Edwards N, Rupnow F, Pashos C, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23:299–314
   PubMed Web of Science ®Google Scholar
• De Graeve D, Smet A, Mehnert A et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23:35–47
   PubMed Web of Science ®Google Scholar
• Laux G, Heeg BMS, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23:49–61
   PubMed Web of Science ®Google Scholar
• Chue PS, Heeg BMS, Buskens E, van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23:62–74
   Google Scholar
• Urdahl H, Knapp M, Edgell ET, et al, on behalf of the SOHO study group. Unit costs in international economic evaluations: resource costing of the schizophrenia outpatient health outcomes study. Acta Psychiatr Scand 2003;107:S41–7
   Google Scholar
• Lindgren P, Stenestrand U, Malmberg K, Jonsson B. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 2005;27:100–110
   PubMed Web of Science ®Google Scholar
• International Monetary Fund. World Economic Outlook Database, July 2006. http://www.imf.org/external/pubs/ft/weo
   Google Scholar
• da Silva E, Pinto C, Sampaio C, et al. Guidelines for economic drug evaluation studies. 1998. Infarmed
   Google Scholar
• Sadock BJ, Sadock VA. Kaplan & Sadock’s Pocket Handbook of Clinical Psychiatry, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2001
   Google Scholar
• Divided attention shared care; from problem areas to quality in the care of patients with schizophrenia. 2000. Schizophrenia Platform the Netherlands. 2000
   Google Scholar
• Neeleman J. A continuum of premature death. Meta-analysis of competing mortality in the psychosocially vulnerable. Int J Epidemiol 2001;30:154–62
   Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16–22
   Google Scholar
• Tollefson GD, Beasly CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 2002;154:457–65
   Google Scholar
• Carpenter W, Buchanan R. Schizophrenia. N Engl J Med 1994;330:681–90
   PubMed Web of Science ®Google Scholar
• McIntyre R, Trakas K, Lin D, et al., and CNOMSS Study Group. Risk of adverse events associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia (CNOMSS). 51st Annual Canadian Psychiatric Association Meeting, 2001, Montreal [Abstract]
   Google Scholar
• Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358–63
   PubMed Web of Science ®Google Scholar
• Csernansky J. Risperidone vs haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long-term double-blind comparison. Biol Psychiatry 2001;47:S31–2
   Web of Science ®Google Scholar
• Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors – a United States perspective. J Clin Psychiatry 1984;45:36–42
   PubMed Web of Science ®Google Scholar
• Health Care Insurance Board. Pharmacopoeia the Netherlands. Amstelveen: Health Care Insurance Board, 2002
   Google Scholar
• Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002;54: 253–64
   Google Scholar
• National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2003. London, NICE
   Google Scholar
• Dolder C, Lacro J, Dunn L, Jeste D. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103–8
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Oehl M, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64:S3–9
   Google Scholar
• Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371–6
   PubMed Web of Science ®Google Scholar
• Kay S. Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel, 1991
   Google Scholar
• Wolthaus J, Dingemans P, Schene A, et al. Caregiver burden in recent-onset schizophrenia and spectrum disorders: the influence of symptoms and personality traits. J Nerv Ment Dis 2005;190:241–7
   Google Scholar
• Cheung P, Schweitzer I, Crowley K, Tuckwell V. Violence in schizophrenia: role of hallucinations and delusions. Schizophr Res 1997;29:181–90
   Google Scholar
• Steinert T, Wolfe M, Gebhardt R Measurement of violence during in-patient treatment and association with psychopathology. Acta Psychiatr Scand 2000;102:107–12
   PubMed Web of Science ®Google Scholar
• Infarmed.December.2003. Lisbon: Instituto Nacional da Farmácia e do Medicamento. http:/www.Infarmed.pt
   Google Scholar
• Ordem dos Médicos. Código Allianz de Nomenclatura e Valor Relativo. de Actos Médicos. 2003
   Google Scholar
• Mahmoud R, Engelhart L, Janagap C, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder; symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:275–86
   PubMed Web of Science ®Google Scholar
• Weiden P, Glazer W. Assessment and treatment selection for “revolving door” inpatients with schizophrenia. Psychiatr Q 1997;68:377–92
   PubMed Web of Science ®Google Scholar
• Arango C, Calcedo Barba A, et al. Violence in inpatients with schizophrenia: a prospective study. Schizophr Bull 1999;25:493–503
   PubMed Web of Science ®Google Scholar
• Cheung P, Schweitzer I, Crowley K, Tuckwell V. Aggressive behaviour in schizophrenia: the role of psychopathology. Aust N Z J Psychiatry 1997;1:62–7
   Google Scholar
• Shaw J. Assessing the risk of violence in patients. BMJ 2000;320:1088–9
   PubMed Web of Science ®Google Scholar
• Hodgins S, Muller-Isberner. Preventing crime by people with schizophrenic disorders: the role of psychiatric services. Br J Psychiatry 2004;185:245–50
   Google Scholar
• Chue P, Devos E, Duchesne I, Leal A, Mehnert A. Hospitalisation rates in patients during long-term treatment with long-acting risperidone injection. Int J Clin Neuropsychopharmacol 2005;5:S128–9
   Google Scholar
• Remington G, Adams M. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40:S5–11
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111–17
   PubMed Web of Science ®Google Scholar
• Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000;29: 1–9
   Google Scholar
• Health Care Insurance Board. Farmacotherapeutisch Kompas 2002. 2002. Amstelveen, Health Care Insurance Board
   Google Scholar
• Ministério da Saúde. Portaria 132/2003 de 5 de Fevereiro. Diário da República, I Série-B, n.30, 2003
   Google Scholar
• McMurran M. Dual diagnosis of mental disorder and substance misuse. 2002. NHS
   Google Scholar
• Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28:43–61
   PubMed Web of Science ®Google Scholar
• Goldner E, Hsu L, Waraich P, Somers J. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002;47:833–43
   PubMed Web of Science ®Google Scholar
• Selten J, Veen N, Feller W, et al. Incidence of psychotic disorders in immigrant groups to the Netherlands. Br J Psychiatry 2001;178:367–72
   PubMed Web of Science ®Google Scholar
• Grinspoon L, et al. Schizoaffective disorder. The Harvard Mental Health Lett 1996;13:1–4
   Google Scholar
• Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23:17–33
   PubMed Web of Science ®Google Scholar
• Eriksson L, Almqvist A, Mehnert A, Eriksson B. Reduction in need for institutional care in chronic schizophrenia subjects switched to long-acting risperidone. 45th Annual and 4th Mediterranean meeting of the Scandinavian college of Neuro-Psychophamacology. Juan-les-Pins [Abstract]
   Google Scholar